To drive precision medicine care forward, the Englander Institute ensures all eligible patients are included in our research cohorts and studies. This journey typically begins with physician’s referral of a patient to our clinical research team. Our team also employs novel patient identification methods to screen potential patients that may be eligible for one of our many precision medicine studies.
Weill Cornell Medicine investigators conduct research-based clinical care. To date, over 4,000 patients across the spectrum of disease groups have enrolled in precision medicine studies. For more information about each of these studies, https://clinicaltrials.gov/.
We have one of the most advanced next generation sequencing initiatives in the nation, thanks to the launch of a large-scale Whole Genome Sequencing (WGS) collaboration. These reports provide a more precise diagnosis for rare diseases and will contribute to the development of new treatments for a range of patients.
The initiative will focus on the disease areas of oncology, cardiovascular, metabolic and neurodegenerative diseases.
A study is to assess the clinical importance of germline mutations in urothelial cancer (UC) by building a comprehensive registry of patients with the disease.
Primary Investigator(s): Bishoy Faltas
Leading cancer scientists working with the New York Genome Center (NYGC) announced that grants are being awarded to fund six projects that address the role of ethnicity in several major cancer types, taking advantage of the diversity of patients being treated at health care institutions throughout the New York City area.
The awards were made under the auspices of a NYGC research initiative, called Polyethnic-1000 (P-1000), which was launched in 2018 to help address cancer care inequities in underserved populations.
“Immunogenomic Determinants of Ethnic Disparities in Clinical Outcomes for Urothelial Cancer Patients,” is a Weill Cornell Medicine study to determine how ethnic diversity affects the clinical outcomes of bladder cancer.
Primary Investigators: Bishoy Faltas, Cora Sternberg, Olivier Elemento
The DIGNITY Study (De-convoluting interactions between genes, the cancer environment, and the immune system to develop therapies that work for you). NCT05134779 Click here to enquire about this study.
Primary Investigator(s): Sandra Demaria, Silvia Formenti, Lisa Newman
The International Center for the Study of Breast Cancer Subtypes (ICSBCS) is tasked with enhancing breast cancer prevention and treatment through advances in research and delivery of care to diverse populations worldwide.
Primary Investigators: Lisa Newman, Melissa Davis
Dermatologic diseases are representative of multisystem illnesses affecting multiple organs, and can have a significant impact on the health and well-being of the patient. The Precision Dermatology Program aims to establish innovative, collaborative research programs.
Primary Investigator(s): Jon Zippin
Primary Investigator(s): Manish Shah, Juan Miquel Mosquera
Primary Investigators: Manish Shah
Primary Investigators: Manish Shah, Pashtoon Kasi
In a study Weill Cornell Medicine, and his team reported that high doses of vitamin C impaired the growth of KRAS mutant and BRAF mutant colorectal tumors. Now with a multimillion dollar grant from Stand Up to Cancer (SU2C)/American Association for Cancer Research, the investigators have moved to human trials to confirm their earlier findings.
Primary Investigators: Manish Shah
Primary Investigators: Kevin Holcomb, Eloise Chapman, Juan Miguel Mosquera
Primary Investigators: Kevin Holcomb, Eloise Chapman, Evelyn Cantillo, Melissa Frey
Primary Investigator(s): Jan Krumsiek, NYP-UES and NYP-QNS surgeons
Primary Investigators: Nasser Altorki
The EIPM is one of four centers in the United States participating in the Human Cancer Models Initiative (HCMI), an international consortium that is generating novel, next-generation, tumor-derived culture models annotated with genomic, clinical, and biospecimen data. HCMI has over 200 organoid models that are available to the research community and whose goal is to generate and annotate up to 1000 next-generation cancer models derived from patient tissues. WCM joins this project through a subcontract with Leidos Biomedical Research, which operates the Frederick National Laboratory for Cancer Research for the National Cancer Institute.
Primary Investigators: Cora Sternberg, Juan Miguel Mosquera, GU Oncology Team
Leading cancer scientists working with the New York Genome Center (NYGC) announced that grants were awarded to fund six projects that address the role of ethnicity in several major cancer types, taking advantage of the diversity of patients being treated at health care institutions throughout the New York City area.
The awards were being made under the auspices of a NYGC research initiative, called Polyethnic-1000 (P-1000), which was launched in 2018 to help address cancer care inequities in underserved populations.
“Molecular Links between Ancestry and Outcome Disparity in Breast and Prostate Cancer Patients Across the African Diaspora in New York City,” is a study to identify molecular links between African ancestry and aggressive forms of breast and prostate cancer and investigate these as a source of racial disparities in cancer outcomes. The P-1000 Prostate initiative is further supported b the Department of Defence Prostate Cancer Research Program (PCRP) Health Disparity Research Award (PI: Mosquera).
Primary Investigator(s): Cora Sternberg, David Nanus, Juan Miguel Mosquera, Jones Nauseef, Olivier Elemento
NIH Grant Funds Lupus Research in Children: A multi-institutional team of scientists, led by researchers at Weill Cornell Medicine's Gale and Ira Drukier Institute for Children's Health, received a five-year $8.3 grant to continue funding a Center for Lupus Research.
Primary Investigator(s): Virginia Pascale
PRISM is a national study of children, adolescents, and young adults who have been infected with the SARS-CoV-2 virus resulting in COVID-19 and/or MIS-C, multisystem inflammatory syndrome in children.
Primary Investigator(s): Virginia Pascual (WCM), Vanderbilt University Medical Center